Brentuximab induced CD30+ cutaneous lymphoma responded to anti-PD1 treatment.
Vasiliki A NikolaouT IliakisL MarinosA EconomidiP PanayiotidisD RigopoulosA J StratigosPublished in: Journal of the European Academy of Dermatology and Venereology : JEADV (2019)